Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
W. Yeo, M. Boyer, H. C. Chung, S. Y.K. Ong, R. Lim, Benny Zee, B. Ma, K. C. Lam, F. K.F. Mo, E. K.W. Ng, R. Ho, S. Clarke, J. K. Roh, P. Beale, S. Y. Rha, H. C. Jeung, R. Soo, B. C. Goh, A. T.C. Chan
Dive into the research topics of 'Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)'. Together they form a unique fingerprint.